Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Feb 28, 2015; 21(8): 2504-2509
Published online Feb 28, 2015. doi: 10.3748/wjg.v21.i8.2504
Published online Feb 28, 2015. doi: 10.3748/wjg.v21.i8.2504
Tenofovir rescue therapy in pregnant females with chronic hepatitis B
Yu-Hong Hu, Min Liu, Wei Yi, Yan-Jun Cao, Hao-Dong Cai, Department of Hepatology, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
Author contributions: Cai HD designed the study; Hu YH, Liu M, Yi W and Cao YJ performed the study; Cai HD analyzed the data; Yi W and Cai HD wrote the manuscript.
Supported by Grants from Beijing Municipal Natural Science Foundation, No. D12110700390000.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Hao-Dong Cai, MD, Chief Physician, Department of Hepatology, Beijing Ditan Hospital, Capital Medical University, No. 8 Jingshun East Street, Beijing 100015, China. chddt@163.com
Telephone: +86-10-84322709 Fax: +86-10-84322708
Received: August 11, 2014
Peer-review started: August 12, 2014
First decision: August 27, 2014
Revised: August 31, 2014
Accepted: October 15, 2014
Article in press: October 15, 2014
Published online: February 28, 2015
Processing time: 200 Days and 17.7 Hours
Peer-review started: August 12, 2014
First decision: August 27, 2014
Revised: August 31, 2014
Accepted: October 15, 2014
Article in press: October 15, 2014
Published online: February 28, 2015
Processing time: 200 Days and 17.7 Hours
Core Tip
Core tip: Tenofovir (TDF) is effective for treating chronic hepatitis B virus (HBV) patients with lamivudine (LAM) or telbivudine (LdT)-resistance. It is classified as category B during pregnancy. There are very few reports regarding the safety of TDF treatment in pregnant patients with LAM or LdT resistance. The present study reports the safety of TDF monotherapy in pregnant females with chronic HBV and LAM or LdT resistance. This study provides preliminary evidence regarding the efficacy and safety of TDF during pregnancy. It also sets an example for further studies exploring the safety profiles of nucleos(t)ide analogs in pregnant females.